Tom Riffelmacher

Tom Riffelmacher

tom-riffel.bsky.social

Professor; University of Cologne; We research Immunometabolism, unconventional T cells, and cardio-oncology.

👤 Joined on 19 November 2024

898

Followers

336

Following

38

Total Posts

📜 Kullanıcı Geçmişi

  • 19 Kas 2024, 05:48
    🎉 Bluesky'e katıldı - İlk kullanıcı adı: @tom-riffel.bsky.social

🚫 Blokladığı Kullanıcılar

❤️ Beğendiği Gönderiler

Nanobodies targeting MR1-antigen complexes are engineered to modulate mucosal-associated invariant T cells and target MR1-ligand complexes on tumors www.science.org/doi/10.1126/... @sciimmunology.bsky.social @thedohertyinst.bsky.social

Show Post

🚨New paper alert!! Out in @insight.jci.org - highlights defects in Vdelta2 T cells in people living with obesity. Importantly we can see bariatric surgery restores these cells!! Led by @ciara.l.flynn but it takes a village. Thanks to funding from HRB. Find it here doi.org/10.1172/jci....

Show Post

Delighted to see over review and concept on the cover of this month's @cp-trendsendomet.bsky.social where we cover GLP-1s & SGLT2i as anti-inflammatory agents- co-authored with @nickjonesimmuno.bsky.social

Show Post

Time is flying by ⌛😱 Recently celebrated the first birthday of my lab at @uni-of-warwick.bsky.social @mechanochemistry.org It's been a lot of fun. Many thanks to my great colleagues and amazing team who makes the science happen. Looking forward to our next scienceventures 🔬👨‍🔬👩‍🔬 #FCS #FLIM

Show Post

Antigenic stimulation in conjunction with cytokine is required for mediating IL-17A production in human MAIT cells https://www.biorxiv.org/content/10.64898/2026.01.27.702041v1

Show Post

Select language

Install App

Install App